STOCK TITAN

Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Balyasny Asset Management L.P. and affiliated entities report beneficial ownership of Crescent Biopharma, Inc. common stock. Through Atlas Private Holdings (Cayman) Ltd., which directly holds 670,000 Shares, and Atlas Diversified Master Fund, Ltd., which directly holds 992,917 Shares, the group may be deemed to beneficially own a total of 1,662,917 Shares of Class A common stock.

These Shares represent approximately 6.03% of Crescent Biopharma’s Class A common stock, based on 27,571,935 Shares outstanding as of April 24, 2026. Each reporting person—Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny—is listed with sole voting and dispositive power over 1,662,917 Shares and no shared power. ADMF and APHC have the right to receive dividends and sale proceeds from these securities.

Positive

  • None.

Negative

  • None.
Beneficial ownership 1,662,917 Shares Total Crescent Biopharma Class A common stock beneficially owned by reporting persons
Ownership percentage 6.03% Portion of Crescent Biopharma Class A common stock beneficially owned
Shares outstanding 27,571,935 Shares Crescent Biopharma Class A common stock outstanding as of April 24, 2026
APHC direct holdings 670,000 Shares Shares of Crescent Biopharma Class A common stock held by Atlas Private Holdings (Cayman) Ltd.
ADMF direct holdings 992,917 Shares Shares of Crescent Biopharma Class A common stock held by Atlas Diversified Master Fund, Ltd.
Signatures date 08/14/2026 Date the reporting persons executed the ownership statement
beneficial owner financial
"Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 6.03%"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
sole voting power financial
"Each of the Reporting Persons has the sole power to vote or to direct the vote of 1662917 shares"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power financial
"Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 1662917 shares"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
investment manager financial
"By virtue of its position as the investment manager of Atlas Private Holdings (Cayman) Ltd."
Schedule 13G regulatory
"based on 27,571,935 7 Shares of class A common stock outstanding as of April 24, 2026"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

How much of Crescent Biopharma (CBIO) does Balyasny Asset Management beneficially own?

Balyasny Asset Management and affiliates may be deemed to beneficially own 1,662,917 Shares of Crescent Biopharma Class A common stock, representing approximately 6.03% of the class, based on 27,571,935 Shares outstanding as of April 24, 2026.

Which entities directly hold Crescent Biopharma (CBIO) shares for Balyasny Asset Management?

The reported Crescent Biopharma Shares are directly held by Atlas Private Holdings (Cayman) Ltd. with 670,000 Shares and Atlas Diversified Master Fund, Ltd. with 992,917 Shares, both investment management clients of Balyasny Asset Management L.P.

What voting power does Balyasny Asset Management report over Crescent Biopharma (CBIO) shares?

Each reporting person is listed with sole power to vote or direct the vote over 1,662,917 Shares of Crescent Biopharma Class A common stock and no shared voting power, reflecting centralized control of voting decisions for these holdings.

What dispositive power does Balyasny Asset Management have over its Crescent Biopharma (CBIO) position?

Each reporting person is described as having sole power to dispose or direct the disposition of 1,662,917 Shares and no shared dispositive power, indicating individual authority within the reporting group over sales or other dispositions of these securities.

Who receives dividends and sale proceeds from Balyasny’s Crescent Biopharma (CBIO) shares?

Atlas Diversified Master Fund, Ltd. (ADMF) and Atlas Private Holdings (Cayman) Ltd. (APHC) have the right to receive dividends and sale proceeds from the reported Crescent Biopharma securities, as investment management clients of Balyasny Asset Management L.P.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





38000Q201

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BALYASNY ASSET MANAGEMENT L.P.
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
BAM GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
Balyasny Asset Management Holdings LP
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
Dames GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
Dmitry Balyasny
Signature:/s/ Dmitry Balyasny
Name/Title:Dmitry Balyasny / Self
Date:08/14/2026